Cantz T (2019). A combined in silico and in vitro study on mouse Serpina1a antitrypsin-deficiency mutants. Scientific reports. 9(1):7486. Dai Z, Song G, Balakrishnan A, Yang T, Yuan Q, Mobus S, Weiss AC [...] sler K, Stitz J, Cantz T , Eggenschwiler R (2018). Functional characterization of the mouse Serpina1 paralog DOM-7. Biol Chem. 399(6):577-82. Advena-Regnery B, Dederer HG, Enghofer F, Cantz T , Heinemann [...] Ziller MJ, Meissner A (2018). Genome-wide tracking of dCas9-methyltransferase footprints. Nat Commun 9(1):597. doi: 10.1038/s41467-017-02708-5. Sgodda M, Dai Z, Zweigerdt R, Sharma AD, Ott M, Cantz T (2017)

Masyarakat Nasional (National Public Health Journal) 2023; 18 (Special Issue 1): 43-48 DOI: https://doi.org/10.21109/kesmas.v18isp1.7021 Abstracts von Vorträgen (Peer-Reviewed) Gartmann J, Bökel A, Egen C [...] Does Successful Treatment of Pain Have an Impact on Mental Health? Med Probl Perform Art 2023; 38 (1): 43-55. DOI: https://doi.org/10.21091/mppa.2023.1006 Krötz M, Quittel F, Reif M, Zerm R, Pranga D, [...] randomized controlled study in breast cancer survivors with cancer-related fatigue. Sci Rep 2023; 13 (1): 2705. DOI: https://doi.org/10.1038/s41598-022-25322-y Lemhöfer C, Sturm C, Loudovici-Krug D, Gutenbrunner

U, Lachmann N. „Hematopoietic stem cell gene therapy for IFNγR1 deficiency protects mice from mycobacterial infections.“ Blood . 2018 Feb 1;131(5):533-545. doi: 10.1182/blood-2017-10-812859. Neehus AL, [...] “Impaired IFN g -Signaling and Mycobacterial Clearance in IFN g R1 Deficient Human iPSC-Derived Macrophages” Stem Cell Reports. 2018 Jan 9;10(1):7-16 2017 Kuhn A, Ackermann M, Mussolino C, Cathomen T, Lachmann [...] Cantz T, Klusmann JH. „Gene correction of HAX1 reversed Kostmann disease phenotype in patient-specific induced pluripotent stem cells.“ Blood Adv . 2017 Jun 2;1(14):903-914. Lopez-Rodriguez E, Gay-Jordi G

2022;13(1):5637 DOI: 10.1038/s41467-022-33193-0 2021 Generation of hiPSC-derived low threshold mechanoreceptors containing axonal termini resembling bulbous sensory nerve endings and expressing Piezo1 and [...] positive: tailored genome engineering meets reprogramming. Cathomen T, Schambach A. Gene Ther. 2010 Jan;17(1):1-3. doi: 10.1038/gt.2009.151. Epub 2009 Nov 12. No abstract available. HOXB4's road map to stem cell [...] 1016/j.jhep.2021.08.011 Conditionally immortalised leukaemia initiating cells co-expressing Hoxa9/Meis1 demonstrate microenvironmental adaptation properties ex vivo while maintaining myelomonocytic memory

-cohort analysis: Increasing disability in younger cohorts. Disability and Health Journal 2021; 14:1. DOI: https://doi.org/10.1016/j.dhjo.2020.100948 Weidemann F, Decker S, Epping J , Örgel M, Krettek [...] estimation of incidence rates: analyses with German claims data. BMC Medical Research Methodology 20(1). Tetzlaff F, Epping J , Sperlich S, Tetzlaff J. (2020). Widening income inequalities in life expectancy [...] stroke-free and stroke-affected life years based on German health insurance data. PloS one. 2020;15(1):e0227541. Sperlich S, Beller J, Epping J, Tetzlaff J, Geyer S (2020). Trends in self-rated health among

Gongoll S, Langner C, Mengel M, Piso P, Klempnauer J, Rüschoff J, Kreipe H, von Wasielewski R: IGF-1R, IGF-1 and IGF-2 expression as potential prognostic and predictive markers in colorectal-cancer. Virchows [...] Elevated numbers of circulating cells in renal transplant recipients. Transplantation 2003; 15; 76(1): 1-4 Woywodt A, Schroeder M, Mengel M, Schwarz A, Gwinner W, Haller H, Haubitz M: Circulating endoth [...] Tech 2003; 13(2): 133-8 Bock O, Serinsöz E, Neusch M, Schlué J, Kreipe H: The Polycythaemia rubra vera-1 gene is constitutively expressed by bone marrow cells and does not discriminate Polycythaemia vera from

Carcinomas with and without Rearrangements of the Tyrosine Kinase Receptors RET and/or NTRK1. J Surg Res 2006; 131(1): 15-25 Pautz D, Herrmann T, Buhr T: [Zystisches Lymphangiom der Niere.] Fortschr Röntgenstr [...] 2006; 132(2): 435-6 Bock O, Hussein K, Neusch M, Schlué J, Wiese B, Kreipe H: Transcription factor Fli-1 expression by bone marrow cells in chronic myeloproliferative disorders is independent of an underlying [...] Jonas U, Machtens S, Serth J: Alteration of subcellular and cellular expression patterns of cyclin B1 in renal cell carcinoma is significantly related to clinical progression and survival of patients. Int

Dr. Heiko Stoff Ort: MHH, Gebäude J1, Hörsaal M * * * 8. April 2016 Aktuelle Positionen in der Medizingeschichte: Sigrid Stöckel zum 60. Geburtstag Ort: MHH, Gebäude J1, Hörsaal H Veranstalter: Institut [...] Club mit Hazem Zohny * * * 7.2.2025 Digital Bioethics Journal Club mit Bjørn Morten Hofmann * * * 2.1.2025 Digital Bioethics Journal Club mit Vasiliki Rahimzadeh * * * 2.12.2024 „Setbacks and Surprises“ [...] Sozialgeschichte der Geburtshilfe Öffentliche Antrittsvorlesung von PD Dr. phil. Wiebke Lisner * * * 16.1.2024 Risikokommunikation in der Krise? Überlegungen zum Umgang mit riskanten Unsicherheiten am Beispiel

Viktor Grünwald, Andres J. Schrader, and Philipp Ivanyi. 2016. “Do Programmed Death 1 (PD-1) and Its Ligand (PD-L1) Play a Role in Patients with Non-Clear Cell Renal Cell Carcinoma?” Medical Oncology [...] avoidable risk?” (Tandem presentation – part 1) in session “Clinical Trials 1”, CEN-IBS 2023 – Basel (CH). https://cen2023.github.io/home/data/ConferenceBook%201.1.pdf 08/2022 - NH Thomas, A Koch, A Großhennig: [...] E. Wacker. 2017. “Costs and Health-Related Quality of Life in Alpha-1-Antitrypsin Deficient COPD Patients.” Respiratory Research 18(1). doi: 10.1186/s12931-017-0543-8. Houben-Wilke, Sarah, Rudolf A. Jörres

Funktion hin zur Aufrechterhaltung der endothelialen Homöostase und zur Reaktion auf Schädigungen. Angpt-1 ist der wichtigste zirkulierende Tie2-Agonist, der schützende Anti-Permeabilitätssignale fördert, während [...] Funktion auf die Aufrechterhaltung der endothelialen Homöostase und die Reaktion auf Schädigungen. Angpt-1 ist der wichtigste zirkulierende Tie2-Agonist, der schützende Anti-Permeabilitätssignale fördert, während [...] bei Patienten mit Sepsis und ARDS zu untersuchen (NucCap-Studie). Intensive Care Med. 2022 Jan;48(1):130-132 Personalisierte Therapie bei Sepsis und ARDS Die biologische Heterogenität, die bei Sepsis